Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
14/10/2026 06:16
BRIEF-Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement Oct 14 (Reuters) - Zealand Pharma A/S ZELA.CO:
SAID ON TUESDAY ZEALAND PHARMA AND GENERATE BIOMEDICINES ENTER COLLABORATION AND LICENSE AGREEMENT TO DEVELOP PROTEIN THERAPEUTICS ENGINEERED WITH AI FOR METABOLIC DISEASES
ZEALAND: GENERATE WILL RECEIVE USD 30 MILLION UP-FRONT, UP TO USD 35 MILLION IN EARLY PRECLINICAL MILESTONES, AND A TOTAL OF NEARLY USD 1.2 BILLION IN MILESTONES
Source text: ID:nGNE66dnPq
Further company coverage: ZELA.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)